HEALTH● LOWAug 13 · Aug 13, 2026, 6:59 PM
Cellectar targets mid-2027 accelerated approval NDA for iopofosine in WM, backed by up to $140M financing
Seeking Alpha Tech
Cellectar aims for accelerated FDA approval by mid-2027 for iopofosine in WM, supported by up to $140 million in financing. This indicates a key strategic move for the company and its drug development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH38m agoShamonda virus: First human case is ‘an alert’, not a reason to panic, says EU health agencyEuroNews [en]HEALTH42m agoBody temperature may drive the higher risk of autoimmune conditions in womenNew ScientistHEALTH57m agoProud Kakinada is at the heart of India’s return to making Penicillin, says Andhra HRD Minister Nara LokeshThe HinduHEALTH1h agoKeralam to adopt calendar-based infectious disease prevention strategyThe Hindu